Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study(NN9662-8160) (NA)

未提供0 个研究点目标入组 25 人开始时间: 待定

适应症

试验速览

暂无简介。

•Male or female (sex at birth).
•Age 18-75 years (both inclusive) at the time of signing the informed consent.
•Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole [mmol/mol]) (both inclusive) as assessed by central laboratory at screening.
•Willingness to obtain a high weight loss (greater than [>] 25% of weight at baseline).

•Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
•Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
•Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.

发起方

未提供